Supernus Pharmaceuticals | SUPN - Current Liabilities


Supernus Pharmaceuticals reported $347.38M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
ANI Pharmaceuticals USD 283.65M 44.14M Jun/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Cara Therapeutics USD 11.26M 216K Mar/2026
Corcept Therapeutics USD 153.8M 4.62M Jun/2026
Eisai JPY 393.64B 53.39B Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
Perrigo USD 1.05B 57.2M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Supernus Pharmaceuticals USD 347.38M 26.55M Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
Xeris Pharmaceuticals USD 189.57M 70.97M Jun/2026